1. Scrip
  2. >>Business

Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?

 
• By Anju Ghangurde

Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether the deal can materially change the fortunes of the product.

Steps
CAN MANNKIND'S PARTNERSHIP WITH CIPLA ALTER AFREZZA'S TRAJECTORY ?

US biopharmaceutical MannKind Corp. has roped in Cipla Ltd. to market its inhaled insulin Afrezza in India, a market with an estimated 73 million diabetics.

The Indian deal is the second international partnership agreement for Afrezza, following a 2017 alliance in Brazil with Biomm S.A. for the product. It comes at a seemingly critical juncture for the financially stretched MannKind as its seeks to take its only FDA-approved product to new markets after Sanofi ended a collaboration and license deal for the product in 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.